februari
two
famili
member
admit
intens
care
ward
hong
kong
special
administr
region
influenzalik
respiratori
ill
avianlik
influenza
virus
isol
patient
one
succumb
infect
first
time
sinc
virus
identifi
human
be
respond
issu
pandem
alert
candid
vaccin
immedi
sought
recent
outbreak
sever
acut
respiratori
syndrom
sar
strike
exampl
rapid
global
spread
emerg
infecti
diseas
howev
even
effect
sar
could
dwarf
could
aris
emerg
influenza
pandem
infect
caus
influenza
viru
zoonosi
anim
reservoir
viru
aquat
bird
popul
world
compel
epidemiolog
link
presenc
viru
poultri
livebird
market
appear
human
be
suggest
influenza
virus
transmit
directli
avian
speci
man
caus
sever
respiratori
diseas
although
control
outbreak
achiev
cull
million
bird
hong
kong
market
episod
demonstr
capabl
effect
global
respons
emerg
influenza
threat
poor
technic
legisl
infrastructur
limit
disturb
find
emerg
event
scientif
commun
unabl
produc
effect
vaccin
even
sever
year
inactiv
human
influenza
vaccin
use
today
deriv
essenti
modifi
virus
exploit
segment
natur
influenza
genom
vaccin
manufactur
laboratori
influenza
network
produc
reassort
viru
carri
circul
viru
gene
segment
encod
haemagglutinin
neuraminidas
major
target
neutralis
antibodi
remain
sixgen
segment
suppli
laboratoryadapt
avirul
strain
result
reassort
viru
antigen
properti
circul
strain
safeti
highyield
properti
first
batch
inactiv
materi
viru
readi
clinic
trial
month
second
case
human
infect
aros
even
today
effect
vaccin
viru
proven
key
reason
delay
product
vaccin
natur
viru
viru
highli
pathogen
human
be
poultri
agent
must
handl
condit
least
biosafeti
level
kill
fertilis
chicken
egg
standard
medium
reassort
respons
pandem
alert
use
revers
genet
rapid
develop
influenza
vaccin
propag
influenza
viru
inactiv
formul
use
vaccin
trait
present
viru
pathogen
natur
virus
link
presenc
addit
basic
residu
haemagglutinin
site
cleavag
step
requir
haemagglutinin
activ
thu
viru
entri
cell
overcom
high
pathogen
viru
polybas
aminoacid
elimin
rapid
reproduc
system
achiev
modificationsi
plasmidbas
revers
geneticsha
develop
past
year
potenti
benefit
revers
genet
gener
attenu
vaccin
candid
highli
pathogen
low
pathogen
influenza
virus
enorm
howev
host
specif
rna
polymeras
promot
use
influenza
reversegenet
system
requir
use
approv
cell
line
limit
practic
option
system
use
manufactur
human
vaccin
vaccinecandid
refer
viru
stock
describ
report
produc
entir
cell
substrat
licens
manufactur
human
vaccin
isto
knowledgeth
first
revers
genet
deriv
influenza
vaccin
suitabl
test
clinic
trial
describ
construct
vaccin
refer
viru
good
manufactur
practic
gmp
grade
facil
less
week
time
viru
isol
find
highlight
speed
new
technolog
implement
respons
influenza
pandem
alert
obtain
whoapprov
vero
cell
whovero
american
type
cultur
collect
manassa
virginia
usa
cell
five
passag
sinc
remov
work
cell
bank
use
rescu
vaccinecandid
viru
plasmid
contain
gene
describ
elsewher
viru
propag
rna
extract
pcr
amplif
haemagglutinin
neuraminidas
gene
clone
obtain
ahong
passag
egg
influenza
network
viru
isol
propag
embryon
chicken
egg
total
rna
extract
infect
allanto
fluid
use
rneasi
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
revers
transcript
carri
primer
amv
revers
transcriptas
roch
indiana
biochem
indianapoli
usa
remov
connect
peptid
haemagglutinin
done
use
pcr
follow
primer
set
amplifi
neuraminidas
gene
ahong
use
primer
pair
pcr
product
purifi
clone
vector
describ
previous
rescu
infecti
viru
clone
cdna
done
gmp
condit
vero
cell
grown
confluenc
cm
flask
trypsinis
trypsinversen
resuspend
ml
optimem
invitrogen
carlsbad
ca
usa
ml
cell
suspens
ad
ml
fresh
optimem
ad
ml
dilut
suspens
well
sixwel
tissu
cultur
plate
cell
per
well
plate
incub
overnight
next
day
g
plasmid
l
transit
transfect
reagent
panvera
madison
wi
usa
ad
optimem
final
volum
l
mixtur
incub
room
temperatur
min
incub
medium
remov
one
well
sixwel
plate
l
optimem
ad
transfect
mix
mixtur
ad
dropwis
cell
h
later
dnatransfect
mixtur
replac
optimem
h
transfect
ml
optimem
contain
gml
l
ethyl
chloromethyl
keton
tpck
treat
trypsin
worthington
biochem
lakewood
nj
usa
ad
cell
h
addit
tpcktrypsin
cultur
supernat
harvest
clarifi
lowspe
centrifug
inject
l
clarifi
supernat
allanto
caviti
individu
pathogenfre
embryon
research
grade
egg
charl
river
spafa
north
franklin
ct
usa
ten
chicken
receiv
intraven
inject
ml
dilut
viru
dilut
ratio
monitor
chicken
sign
diseas
day
use
intraven
pathogen
index
approv
offic
intern
epizooit
oie
addit
took
tracheal
cloacal
swab
ml
media
day
day
infect
assay
presenc
viru
inject
ml
three
embryon
chicken
egg
haemagglutin
activ
allanto
fluid
egg
assess
incub
day
pathogen
test
ferret
test
pathogen
vaccin
five
young
adult
male
ferret
marshal
farm
north
rose
ny
usa
age
month
weight
kg
shown
haemagglutin
inhibit
assay
seroneg
current
circul
human
influenza
virus
virus
anaesthetis
ferret
inhal
isofluran
infect
intranas
egg
infecti
dose
eid
ml
vaccin
reassort
viru
wildtyp
viru
monitor
ferret
per
day
sign
sneez
inappet
inact
record
rectal
temperatur
bodyweight
day
infect
ferret
anaesthetis
ketamin
mgkg
collect
nasal
wash
use
ml
steril
phosphatebuff
salin
pb
contain
antibiot
measur
titr
viru
wash
eid
assay
assess
pathogen
virus
collect
tissu
sampl
lung
brain
olfactori
bulb
spleen
intestin
viru
isol
histopatholog
analysi
time
death
case
three
ferret
euthanasia
day
infect
tissu
fix
neutral
buffer
formalin
process
embed
paraffin
section
g
stain
haematoxylin
eosin
examin
light
microscopi
blind
fashion
test
stabil
vaccin
viru
propag
made
consecut
passag
viru
embryon
chicken
egg
dilut
viru
made
pb
ml
solut
inject
allanto
caviti
four
embryon
chicken
egg
egg
incub
day
incub
egg
candl
determin
embryo
viabil
chill
harvest
ml
allanto
fluid
egg
harvest
sampl
pool
togeth
test
haemagglutin
activ
reinject
anoth
four
egg
sponsor
role
studi
design
collect
analysi
interpret
data
write
report
decis
submit
manuscript
public
first
challeng
face
produc
vaccin
ahong
attenu
viru
prepar
mass
product
previou
experi
shown
remov
basic
aminoacid
haemagglutinin
cleavag
site
substanti
attenu
pathogen
influenza
virus
use
pcrbase
mutagenesi
approach
replac
cleavag
site
encod
haemagglutinin
gene
ahong
avirul
atealhong
figur
modifi
haemagglutinin
gene
neuraminidas
gene
ahong
clone
individu
vector
two
result
plasmid
six
plasmid
encod
remain
protein
transfect
whoapprov
vero
cell
gmp
condit
rescu
vaccin
seed
viru
h
transfect
isol
area
cytopath
effect
could
seen
vero
monolay
although
addit
g
aliquot
tpcktreat
trypsin
everi
h
led
proport
increas
cytopath
effect
requir
success
viru
rescu
candid
vaccin
strain
grew
high
titr
subsequ
amplif
egg
haemagglutin
titr
caus
embryo
death
vaccin
seed
viru
unabl
form
plaqu
madindarbi
canin
kidney
mdck
cell
absenc
trypsin
trait
consist
influenza
virus
lack
polybas
cleavag
site
antigen
indistinguish
parent
viru
haemagglutin
inhibit
assay
rescu
viru
fulli
sequenc
ident
plasmid
use
creation
assess
pathogen
vaccin
seed
viru
compar
properti
viru
wildtyp
ahong
ferret
chicken
stark
contrast
wildtyp
viru
lethal
chicken
within
h
infect
intraven
administr
dilut
result
sign
infect
chicken
unabl
detect
viru
swab
cloaca
trachea
inocul
bird
compar
ahong
attenu
ferret
inocul
intranas
eid
viru
ferret
infect
ahong
inappet
weight
loss
figur
one
infect
anim
die
day
infect
second
kill
day
infect
hindlimb
paralysi
infect
anim
characteris
viral
shed
day
infect
replic
viru
lower
respiratori
tract
olfactori
bulb
determin
viru
isol
ahong
infect
anim
mild
mononuclear
cell
infiltr
mening
tracheal
submucos
mucou
gland
extens
bronchopneumonia
pneumat
infiltr
progress
sever
bronchi
pleura
bronchi
bronchiol
contain
slough
necrot
epitheli
cell
numer
mononuclear
cell
neutrophil
alveoli
consolid
inflammatori
cell
fibrin
figur
contrast
ferret
infect
lose
weight
figur
seem
remain
healthi
studi
day
figur
viru
detect
nasal
wash
anim
day
day
infect
viru
recov
upper
respiratori
tract
light
microscopi
mening
trachea
infect
ferret
inflammatori
infiltr
neutrophil
note
occasion
pulmonari
bronchi
result
clearli
show
attenu
view
find
viru
safe
handl
standard
precaut
contain
facil
mechan
requir
accumul
basic
aminoacid
haemagglutinin
cleavag
site
entir
understood
want
confirm
alter
cleavag
site
remain
stabl
multipl
passag
embryon
chicken
egg
passag
egg
would
occur
transit
amplif
refer
viru
vaccin
stock
rescu
viru
stabl
continu
serial
passag
embryon
egg
detect
chang
nucleotid
sequenc
haemagglutinin
cleavag
site
passag
evid
chang
pathogen
viru
note
one
dead
embryo
passag
haemagglutin
activ
evid
egg
embryo
death
seen
passag
strongli
suggest
death
relat
viru
replic
haemagglutin
titr
passag
rang
appar
trend
increas
decreas
titr
subsequ
passag
rapid
respons
term
potenti
vaccin
refer
viru
product
outbreak
differ
strikingli
respons
episod
differ
attribut
new
scientif
technolog
avail
importantli
infrastructur
viru
surveil
hong
kong
develop
sinc
first
case
influenza
hong
kong
may
yet
sever
month
elaps
viru
final
characteris
viru
caus
agent
identifi
hour
admiss
patient
hospit
increas
awar
surveil
avail
reagent
identifi
influenza
virus
subtyp
bode
well
rapid
identif
virus
aris
futur
interspeci
transfer
event
coordin
intern
vaccin
develop
time
distribut
candid
virus
import
step
develop
vaccin
pandem
emerg
despit
heighten
secur
document
requir
ship
receiv
potenti
bioterror
agent
sar
outbreak
shown
true
emerg
global
distribut
feasibl
although
pertin
prepar
futur
pandem
stockpil
potenti
vaccin
strain
situat
ongo
outbreak
throughout
asia
http
wwwwhoint
highlight
fact
focu
pandem
plan
must
go
implement
technolog
rapidli
produc
vaccin
field
isol
although
virus
similar
ahong
circul
bird
popul
virus
antigen
distinct
despit
high
genet
similar
guan
peiri
js
unpublish
data
aminoacid
differ
globular
head
haemagglutinin
seem
respons
much
antigen
differ
mean
even
vaccin
previous
prepar
genet
similar
precursor
virus
might
provid
adequ
protect
may
well
face
potenti
pandem
situat
futur
rapid
product
match
vaccin
neededa
point
highlight
outbreak
although
refer
viru
describ
report
prepar
viru
isol
similar
geograph
region
year
earlier
share
limit
antigen
crossreact
virus
hyperimmun
sheep
serum
sampl
produc
purifi
haemagglutinin
least
sixfold
reduc
haemagglutin
inhibitori
activ
compar
ahong
find
show
technic
capabl
respond
rapidli
outbreak
safe
stabl
refer
viru
still
much
accomplish
virus
fulli
use
pandem
interpandem
influenza
vaccin
product
use
revers
genet
introduc
number
new
process
influenza
vaccin
manufactur
encount
standard
reassort
method
one
obviou
need
cultur
cell
although
vero
mdck
cell
develop
substrat
growth
influenza
vaccin
addit
requir
use
cell
revers
genet
unfortun
number
suitabl
cell
line
small
addit
regulatori
requir
choic
cell
also
limit
technolog
plasmid
base
reversegenet
system
necessit
use
cell
primat
origin
vero
cell
line
probabl
option
current
abl
meet
regulatori
technic
demand
shown
vero
cell
use
success
rescu
virus
backbon
use
system
other
demonstr
suitabl
vero
cell
altern
influenza
viru
reversegenet
system
although
cultur
vero
cell
easili
obtain
cell
fulli
test
licens
cell
bank
like
accept
vaccin
manufactur
issu
must
acknowledg
access
cell
must
incorpor
part
futur
pandem
plan
futur
threat
influenza
pandem
address
use
technolog
describ
report
seem
inevit
despit
presenc
low
pathogen
surrog
strain
recent
human
death
influenzalik
ill
caus
highli
pathogen
viru
netherland
reinforc
fact
futur
outbreak
probabl
occur
reversegenet
technolog
provid
logicaland
possibl
onlyway
respond
rapidli
effect
although
respons
outbreak
influenza
shown
current
scientif
capabl
suffici
respond
threat
still
legal
infrastructur
barrier
overcom
barrier
includ
licens
intellectu
properti
issu
surround
essenti
genet
modifi
organ
yet
difficulti
insurmount
pandem
scare
ongo
outbreak
forc
commerci
regulatori
parti
address
issu
urgenc
develop
vaccin
refer
viru
ongo
attempt
creat
viru
challeng
respond
threat
influenza
pandem
must
support
largescal
manufactur
vaccin
clinic
trial
new
vaccin
manipul
revers
genet
r
j
webbi
r
perez
j
coleman
j
h
knight
e
tuomanen
r
g
webster
design
studi
r
j
webbi
much
construct
vaccin
seed
viru
r
perez
develop
construct
plasmid
templat
guan
j
peiri
characteris
isol
initi
viru
j
e
rehg
particip
design
analysi
anim
safeti
test
candid
vaccin
seed
viru
e
govorkova
particip
safeti
test
candid
vaccin
seed
viru
l
r
mcclainmoss
particip
prepar
gmp
document
process
involv
reconstitut
vaccin
seed
viru
